Adaptimmune Therapeutics PLC Quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
Summary
Adaptimmune Therapeutics PLC quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount history and growth rate from Q1 2019 to Q3 2024.
  • Adaptimmune Therapeutics PLC Lessee, Operating Lease, Liability, Undiscounted Excess Amount for the quarter ending September 30, 2024 was $8.29M, a 50.4% increase year-over-year.
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Quarterly (USD)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $8.29M +$2.78M +50.4% Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $4.17M -$1.9M -31.3% Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $4.62M -$997K -17.8% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $5.14M -$755K -12.8% Dec 31, 2023 10-K 2024-03-06
Q3 2023 $5.52M -$425K -7.15% Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $6.07M -$618K -9.24% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $5.62M -$1.83M -24.5% Mar 31, 2023 10-Q 2023-05-12
Q4 2022 $5.9M -$1.65M -21.9% Dec 31, 2022 10-K 2023-03-06
Q3 2022 $5.94M -$2.04M -25.5% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $6.69M Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $7.44M Mar 31, 2022 10-Q 2022-05-09
Q4 2021 $7.55M +$1.25M +19.9% Dec 31, 2021 10-K 2022-03-14
Q3 2021 $7.98M Sep 30, 2021 10-Q 2021-11-04
Q4 2020 $6.3M -$1.59M -20.2% Dec 31, 2020 10-K 2021-02-25
Q4 2019 $7.89M Dec 31, 2019 10-K 2020-02-27
Q3 2019 $8.11M Sep 30, 2019 10-Q 2019-11-06
Q2 2019 $8.67M Jun 30, 2019 10-Q 2019-08-01
Q1 2019 $6.45M Mar 31, 2019 10-Q 2019-05-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.